Navigation Links
Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Date:9/23/2008

ur PL-3994 program," stated Dr. Carl Spana, Palatin's President and Chief Executive Officer. "A clinical study is targeted to start later this calendar year which will randomize chronic heart failure patients to receive daily subcutaneous injections of PL-3994 in addition to their existing drug regimens. While existing medications are effective in reducing symptoms, reducing the rate of hospitalization and extending life, chronic heart failure patients nonetheless have poor prognoses. Thus, there is clearly a significant medical need for newer agents which can provide further improvement."

About Heart Failure (HF)

Currently in the U.S., HF affects over 5 million people with 550,000 new cases of HF diagnosed each year. Despite the treatment of HF with multiple drugs, almost all HF patients will experience at least one episode of acute HF that requires treatment with intravenous medications in the hospital. There were over 1.1 million hospitalizations for HF in 2004. Heart failure has tremendous human and financial costs. Estimated direct costs in the U.S. for HF were $29.6 billion in 2006.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ALEXANDRIA, Va. , May 22, 2013  Viral hepatitis ... More than 75 percent of those with hepatitis C are ... and C Testing and Awareness Day in the U.S. House ... pm in the Rayburn Foyer of the Rayburn House Office ... The American Association for the Study of Liver Diseases ...
(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 ... clinical data presented from the DEFLECT-I study demonstrates that ... brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) ... Heart Scientific Advisory Board announces consensus on the importance ... the importance and need for cerebral protection during cardiovascular ...
Breaking Medicine Technology:Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4
... Sept. 13 COPAN announced this week that it ... flocked swabs, FLOQSwabs, for collection and transfer of biological ... latest addition to a growing number of patents held ... flocked swabs for collection and transfer of biological samples, ...
... "Dan Rather Reports" will present an investigation into the ... drugs like Viagra or Cialis, these are counterfeit versions ... treatment of Alzheimer,s and Casodex, used to treat prostate ... for criminals while, potentially robbing unsuspecting victims of something ...
Cached Medicine Technology:COPAN Secures Japanese Patent for its Flocked Swab Innovation 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 3Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 4Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 5
(Date:5/23/2013)... (PRWEB) May 23, 2013 Ezell Law ... in practice. For 25 years, Jeff Ezell has ... advice with a focus on personal injury cases ... worked for insurance companies, he offers clients a uniquely ... companies operate, which enables him better serve his clients. ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Greenville ... that all team members and doctors have recently ... professional rescuer with an Automated External Defibrillator (AED). ... (AED) is a medical device designed to analyze ... to victims of ventricular fibrillation to restore the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 OnSomble, Inc. ... nurse understanding of the professional role and empower nurses ... Joy, vice president of patient care services and chief ... nurses are excellent clinicians, and we want to help ... them that to lead they must follow, encourage them ...
(Date:5/23/2013)... Better Life Maids of Portland Oregon is putting ... its one of a kind green house cleaning service in ... completed May 29th, and a soft opening scheduled for June ... training in Portland recently and will travel to St. Louis ... "It really is a lot to take in" stated Heather ...
(Date:5/23/2013)... PhD Box has introduced a ... the research process by offering assistance for Thesis Proposals. The ... of services that the company provides for research consultation in ... dedicated proposal writing service is that this is the stage ... research process find it difficult to draft a proposal as ...
Breaking Medicine News(10 mins):Health News:Ezell Law Firm Celebrates 25 Years in Practice 2Health News:Greenville Oral & Maxillofacial Surgeons Announce CPR Re-Certification 2Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2
... ... that wish to host continuing medical education courses at their medical facility in 2010. This ... well as reduce their overall costs to educate their physical therapy and occupational therapy team ... ...
... OAKLAND, Calif., Dec. 4 Herpes zoster, also known as ... against chicken pox, according to a Kaiser Permanente study in ... , The study, the largest of its kind, used ... with the varicella (chicken pox) vaccine from 2002 to 2008 ...
... Dec. 3 The Cancer Center at Harrington ... announced today. , "We expect to start seeing patients immediately," ... , The approval was granted today by the Massachusetts Department ... the facility. , The opening of The Cancer Center ...
... , CHICAGO, Dec. 3 ... United States District Court for the Southern District of ... disclosed $350 million settlement that would resolve a class-action ... the AMA, Medical Society of the State of New ...
... outperforms widely used sulfonylureas, but each patient will be different, ... A class of drugs still taken by millions of people ... of dying and heart failure than the newer treatment metformin, ... diabetes treatment, performed less well than metformin in a study ...
... ... ... nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) vaccination clinics ... Crystal Lake and McHenry and will be open as follows: ,   ...
Cached Medicine News:Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 2Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 3Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: